By CERBIOS-PHARMA SA
Cerbios-Pharma to participate in high prestige BIO DIGITAL 2021 convention
Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) will represent its PROVEO Division for end-to-end development of Antibody Drug Conjugates (ADCs) at the upcoming high prestige BIO DIGITAL 2021 online convention.
Cerbios-Pharma has a long-standing relationship with the Biotechnology Innovation Organization (BIO) that organises the convention.
This year’s digital event will focus on hot topics affecting the biotech world, particularly the COVID-19 coronavirus pandemic, with speakers including America’s ‘Epidemiologist-in-Chief’, Dr. Anthony Fauci, and Pfizer CEO Dr. Albert Bouria.
Cerbios will be an active participant from the convention’s Virtual Swiss Biotech Association Pavilion and will network via the event’s Partnering One platform. The company will be represented at BIO DIGITAL by its Business Development Manager, Dr. Vitor Sousa, along with Business Developer, Matteo Aronis and Marketing & Sales Manager, Valentino Mandelli.
“BIO DIGITAL 2021 will provide Cerbios-Pharma and our PROVEO Division with a global platform from which to communicate our latest developments and connect with existing and prospective partners,” commented Dr. Sousa.
A major topic for conversation at BIO DIGITAL will be implications of recent reorganization of PROVEO, now entirely hosted as a division within Cerbios, which is now responsible for communication, logistics and program management.
Tailored ADC services
The move is designed to help PROVEO handle its expanding business and client portfolio for the partners AGC Biologics for mAb manufacturing and and Oncotec Pharma Produktion for F&F.
This will further improve the PROVEO ADC offer of a tailored service platform with clear and flexible contractual framework, delivering a simplified supply chain from payload and mAb to conjugation and F&F supporting clinical development and commercial manufacturing of ADCs.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies (mAbs), recombinant proteins and antibody drug conjugates (ADCs).
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to support a successful registration. Cerbios is a worldwide presence with partners in Europe, USA and Japan.
Cerbios Division, PROVEO™, in partnership with AGC Biologics and Oncotec, focus on integrated ADC manufacturing solutions.
PROVEO can offer a ADCs end-to-end service from drug substance development till sterile Fill & Finish.
Learn more at: https://cerbios.swiss
About BIO Digital 2021
The Biotechnology Innovation Organization (BIO) is the world’s largest biotech advocacy association, representing member companies, biotechnology groups, academic and research institutions, and related organizations across the USA and in more than 30 countries worldwide.
Its latest BIO International Convention is being staged as a fully online virtual event, BIO DIGITAL 2021, that will spotlight biotech’s transformative role and impact on today’s four key challenges: COVID-19, social justice, the economy and climate change.
BIO DIGITAL 2021 will be staged in two parts: two days of preliminary Innovation Stage presentations on June 10-11 to showcase innovative companies, followed by five days of BIO Digital Week from June 14 that will feature a full conference and networking.
Keynote speakers will include Pfizer CEO Dr. Albert Bouria and Dr. Anthony Fauci, who has been leading the US response to the COVID-19 crisis as head of the National Institute of Allergy and Infectious Diseases.
Further information at: https://www.bio.org/events/bio-digital